Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Emberton

Showing results (311-320 of 474) with videos related to

Pageof 48
Sort By:
BMJ Open|August 22, 2023
Use of artificial intelligence in the detection of primary prostate cancer in multiparametric MRI with its clinical outcomes: a protocol for a systematic review and meta-analysisMaya Thomas, Sanjana Murali, Benjamin Scott S Simpson, et al.
BJU International|June 25, 2011
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE studyMichael Marberger, Stephen J Freedland, Gerald L Andriole, et al.
Nature Reviews. Urology|July 19, 2019
Multiparametric MRI for prostate cancer diagnosis: current status and future directionsArmando Stabile, Francesco Giganti, Andrew B Rosenkrantz, et al.
Medical Physics|February 15, 2018
Technical Note: Error metrics for estimating the accuracy of needle/instrument placement during transperineal magnetic resonance/ultrasound-guided prostate interventionsEster Bonmati, Yipeng Hu, Barbara Villarini, et al.
The Journal of Urology|July 24, 2020
Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis <i>J Urol</i> 2020; doi: 10.1097/JU.0000000000001157Vasilis Stavrinides, Francesco Giganti, Shonit Punwani, et al.
The Lancet. Oncology|April 20, 2012
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyHashim U Ahmed, Richard G Hindley, Louise Dickinson, et al.
Urology|December 5, 2020
Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and QualityJoseph M Norris, Clare Allen, Rhys Ball, et al.
Journal of Robotic Surgery|April 13, 2022
Diagnostic potential of radiological apical tumor involvementCasril Liebert, Naomi Morka, Pranav Satish, et al.
European Urology Oncology|January 1, 2021
Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysisArmando Stabile, Elio Mazzone, Giuseppe O Cirulli, et al.
BJU International|November 13, 2020
Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still outJoseph M Norris, Lina M Carmona Echeverria, Benjamin S Simpson, et al.
Pageof 48

Showing results (311-320 of 474) with videos related to

Sort By:
Pageof 48
BMJ Open|August 22, 2023
Use of artificial intelligence in the detection of primary prostate cancer in multiparametric MRI with its clinical outcomes: a protocol for a systematic review and meta-analysisMaya Thomas, Sanjana Murali, Benjamin Scott S Simpson, et al.
BJU International|June 25, 2011
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE studyMichael Marberger, Stephen J Freedland, Gerald L Andriole, et al.
Nature Reviews. Urology|July 19, 2019
Multiparametric MRI for prostate cancer diagnosis: current status and future directionsArmando Stabile, Francesco Giganti, Andrew B Rosenkrantz, et al.
Medical Physics|February 15, 2018
Technical Note: Error metrics for estimating the accuracy of needle/instrument placement during transperineal magnetic resonance/ultrasound-guided prostate interventionsEster Bonmati, Yipeng Hu, Barbara Villarini, et al.
The Journal of Urology|July 24, 2020
Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis <i>J Urol</i> 2020; doi: 10.1097/JU.0000000000001157Vasilis Stavrinides, Francesco Giganti, Shonit Punwani, et al.
The Lancet. Oncology|April 20, 2012
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyHashim U Ahmed, Richard G Hindley, Louise Dickinson, et al.
Urology|December 5, 2020
Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and QualityJoseph M Norris, Clare Allen, Rhys Ball, et al.
Journal of Robotic Surgery|April 13, 2022
Diagnostic potential of radiological apical tumor involvementCasril Liebert, Naomi Morka, Pranav Satish, et al.
European Urology Oncology|January 1, 2021
Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysisArmando Stabile, Elio Mazzone, Giuseppe O Cirulli, et al.
BJU International|November 13, 2020
Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still outJoseph M Norris, Lina M Carmona Echeverria, Benjamin S Simpson, et al.
Pageof 48